Clearbridge BioMedics raises USD7.2M Series B from Vertex Venture, others

Clearbridge BioMedics, Singapore-based medical tech company, has today announced a new series B venture round of SGD 9M (USD 7.2M). Vertex Venture Holdings, a wholly owned venture capital arm of Temasek Holdings, is the lead investor.

The startup’s flagship product is the ClearCell System, which consists of patent-pending CTChips that are able to detect, isolate, and retrieve tumor cells from blood samples obtained from patients. The isolated tumor cells can then be stained for identification and analysis.

The technology, which has applications in cancer screening, diagnosis, medication, and treatment monitoring, is designed to be a form of non-invasive liquid biopsy — or medical test. The company already has customers in Asia, Europe, and North America.

Other investors in this round includes government co-funding scheme SPRING Seeds Capital, Clearbridge BSA, Biosensors International founder Lu Yoh Chie, and existing shareholder BioVeda.

Lu will also join Clearbridge BioMedics’ board of directors.

Visit VentureDex for more information about funding options for startups in Asia.